Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...1516171819202122232425...208209»
  • ||||||||||  Leqembi (lecanemab-irmb) / Biogen, Eisai, SHR-1707 / Jiangsu Hengrui Pharma
    Clinical, Journal:  Drug Development. (Pubmed Central) -  Dec 25, 2025   
    P2
    The study will investigate the long-term efficacy and safety of SHR-1707.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Observational data, Journal:  Efficacy and safety of flumatinib in adults with Ph-positive ALL: a prospective observational study. (Pubmed Central) -  Dec 25, 2025   
    Flumatinib combined with chemotherapy induced high remission rates and deep molecular responses in newly diagnosed Ph+ ALL patients, with a favorable safety profile. However, patients with CML-LBP or high-risk Ph+ ALL had poor treatment responses and outcomes, indicating the need for more aggressive intervention strategies in this high-risk population.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, fulvestrant / Generic mfg.
    Journal:  Case Report: Solitary scalp metastasis after surgery for invasive ductal carcinoma of the breast. (Pubmed Central) -  Dec 25, 2025   
    Consequently, the patient received localized radiotherapy to these sites while continuing the original treatment protocol. This case highlights the diagnostic challenges of atypical scalp metastases in breast cancer and underscores the importance of early detection and prompt initiation of comprehensive treatment.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, temozolomide / Generic mfg.
    Biomarker, Journal:  Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide. (Pubmed Central) -  Dec 24, 2025   
    Enrichment analysis showed that genes related to cell proliferation were also down-regulated in the long-survival benefit group, while the expression of signaling pathway genes related to cell activation, and immune response was significantly up-regulated. Our study suggests that the combination of apatinib and TMZ may potentially provide clinical benefits in treating rGBM by modulating genes associated with cell proliferation, promoting apoptosis, regulating hypoxia, and enhancing immune response within the tumor microenvironment.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Journal, Monotherapy:  Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-na (Pubmed Central) -  Dec 22, 2025   
    She achieved a partial response within one month and has maintained disease control for over 31 months, with only mild intermittent diarrhea. This case provides real-world evidence supporting the potential of pyrotinib as an effective first-line treatment for HER2-mutant NSCLC, particularly in patients with the Y772_A775dup variant and concurrent EGFR alterations, and highlights the need for further clinical investigation in this setting.
  • ||||||||||  M9466 / EMD Serono
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov) -  Dec 21, 2025   
    P1,  N=3, Terminated, 
    This study provided the possibility of an efficient and low toxicity nanodrug carrier platform. N=54 --> 3 | Trial completion date: Apr 2026 --> Dec 2025 | Suspended --> Terminated | Trial primary completion date: Apr 2026 --> Dec 2025; Sponsor Decision
  • ||||||||||  SHR-7367 / Jiangsu Hengrui Pharma
    Enrollment open:  A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov) -  Dec 21, 2025   
    P1/2,  N=100, Recruiting, 
    N=54 --> 3 | Trial completion date: Apr 2026 --> Dec 2025 | Suspended --> Terminated | Trial primary completion date: Apr 2026 --> Dec 2025; Sponsor Decision Not yet recruiting --> Recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Enrollment change, Trial initiation date:  Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (clinicaltrials.gov) -  Dec 21, 2025   
    P2,  N=59, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=440 --> 59 | Initiation date: Jan 2026 --> Mar 2025
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Enrollment open:  A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) -  Dec 21, 2025   
    P3,  N=400, Recruiting, 
    Not yet recruiting --> Recruiting | N=440 --> 59 | Initiation date: Jan 2026 --> Mar 2025 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Bioengineered Anti-PD-L1 Functionalized Nanoplatform for Targeted Delivery and Tumor Immune Reprogramming Against Colorectal Cancer. (Pubmed Central) -  Dec 15, 2025   
    Furthermore, Apatinib-ExoaPD-L1 reduced the population and suppressive function of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), thereby effectively reversing immune suppression and amplifying the antitumor immune response. Collectively, our findings demonstrated that Apatinib-ExoaPD-L1 is a safe and effective exosome-based therapeutic platform, offering a promising strategy to convert immunologically "cold" tumors into "hot" ones and improve clinical outcomes in CRC.
  • ||||||||||  Review, Journal:  BH19 'JAK in the box?' Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata. (Pubmed Central) -  Dec 12, 2025   
    Long-term safety data were scarce, with only one study (the phase IIb/III ALLEGRO trial on ritlecitinib) extending to 2 years, while others had follow-ups of 52 weeks or shorter...Given the chronic nature of AA and the potential for extended use of JAK inhibitors, further long-term studies are necessary to better assess the risks of malignancies, cardiovascular events and other rare but serious AEs associated with this drug class. Although short-term studies indicate efficacy and tolerability, the absence of longitudinal research underpins the need for cautious clinical use and informed patient decision making.
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03) (clinicaltrials.gov) -  Dec 11, 2025   
    P2,  N=52, Completed, 
    This novel regimen demonstrated exploratory efficacy and a favorable safety profile, warranting further validation in future randomized controlled studies. Recruiting --> Completed | N=100 --> 52 | Trial completion date: Dec 2026 --> Dec 2024 | Trial primary completion date: Apr 2026 --> Dec 2024